Journal of oncology research and therapy最新文献

{"title":"Pembrolizumab with or without Chemotherapy for First-Line Palliative Treatment for PD-L1 High-Positive Advanced Non-Small Cell Lung Cancer: A Monocentric Analysis","authors":"","doi":"10.29011/2574-710x.10147","DOIUrl":"https://doi.org/10.29011/2574-710x.10147","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74810328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Benefit of Early Postoperative Radiotherapy and Diagnostic Value of Serologic Markers on Women with Uterine Sarcoma and Carcinosarcoma","authors":"Eva Meixner, P. Hoegen, E. Sandrini, Robert J. Wolf, L. Michel, K. Smetanay, A. Schneeweiss, J. Debus, -. JulianeHörner, Rieber","doi":"10.29011/2574-710x.10144","DOIUrl":"https://doi.org/10.29011/2574-710x.10144","url":null,"abstract":"Introduction : Women with uterine sarcoma represent a rare heterogenous group with unproven evidence regarding the optimal adjuvant treatment. We aimed to evaluate outcomes and the impact of postoperative radiotherapy (RT). Methods : We retrospectively identified 51 patients, treated with curative adjuvant pelvic radio(chemo)therapy for carcinosarcoma (n=30), leiomyosarcoma (n=14) and endometrial stromal sarcoma (n=7) between 2001-2021. Blood counts and serologic markers were documented prior to surgery, pre- and post-RT. Results : With a median follow-up of 34.7 months, overall survival (OS) 1-, 2- and 5-year rates were 89.9%, 73.3% and 51.7%, respectively, and significantly inferior with positive nodal and resection status, cervical and parametrial infiltration, with higher age and FIGO-stage. A shorter time interval from surgery to RT and normal preoperative leukocyte counts were identified as significantly favorable. Distant control (DC) rates were 84.0% and 60.7% and local control (LC) were 93.7% and 88.2% for 1 and 5 years, respectively, and significantly inferior with a higher FIGO stages, positive resection margins and serosal involvement. DC was poor for cervical infiltration, positive nodal status and with higher Glasgow-Prognostic-Scores. Treatment caused strong declines in leukocyte and hemoglobin levels; however, only moderate toxicity was observed (CTCAE grade <4). Conclusion : RT shortly (≤8 weeks) after hysterectomy was well tolerated achieving efficient LC, but with a significant decrease in blood counts. This study confirms the poor OS of uterine sarcoma due to high failures in DC and shows evidence for the correlation of preoperative leukocyte count and pre-RT Glasgow-Prognostic-Score for prognosis.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81162117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees Whose Spouses have Cancer Conditions in the United States","authors":"","doi":"10.29011/2574710x.010143","DOIUrl":"https://doi.org/10.29011/2574710x.010143","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88410821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees With Cancer Conditions in the United States","authors":"","doi":"10.29011/2574-710x.010142","DOIUrl":"https://doi.org/10.29011/2574-710x.010142","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90390941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Bone Marrow Hypoplasia in a Combined Treatment with Anti PD 1/CTLA-4 in a Patient with Melanoma: A Case Report and Literature Review","authors":"Manuel Zoppi, Aramburu Tomas, Pinna Diego Martin, Carranza Omar","doi":"10.29011/2574-710x.10138","DOIUrl":"https://doi.org/10.29011/2574-710x.10138","url":null,"abstract":"Immunotherapy with monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed death-1 receptor and its ligand PD-L1 has become standard of care for an increasing number of indications [1]. In recent years, an increasing number of patients have been exposed to these drugs with a chance of developing toxicities from these treatments [2]. Severe-hematological toxicities have been rarely reported in the literature. We reported a case of a severe bone marrow hypoplasia associated with immunotherapy. The diagnosis was confirmed with bone marrow biopsy after ruling out other pathologies associated with this entity.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"os-52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87367023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosomal MicroRNA -142-5p in Serum is a Prognostic Factor in Cutaneous Squamous Cell Carcinoma","authors":"H. Han, Jong Yeup Kim, S. Jeon, J. Choi","doi":"10.29011/2574-710x.10135","DOIUrl":"https://doi.org/10.29011/2574-710x.10135","url":null,"abstract":"Purpose: Exosomal microRNAs in tumor microenvironment can have a significant impact on the plasticity of cancer cells leading to the promotion of metastasis and angiogenesis. MicroRNAs expressed in tumor cells, fibroblasts, immune cells, and endothelial cells are known to target mRNAs in origin cells to promote tumor growth and metastasis, and induce changes in cell phenotype and expression and secretion of cytokines. MicroRNA expression patterns, which change depending on the tumor type, provide clues that can serve as a biological marker for diagnosis, determining the outcome of the disease, and treatment responses. However, there has been no definitive study on the relationship between exosomal microRNAs and prognosis in cutaneous squamous cell carcinoma. Here, we studied the association between prognosis of cutaneous squamous cell carcinoma patients and microRNAs detected in blood serum. Patients and methods: We enrolled 43 patients with various stages of cutaneous squamous cell carcinoma. Blood samples from patients were obtained and serum was separated by the using centrifuge. microRNAs were purified from serum exosomes, and microRNA sequencing was performed. The microRNA expression profiles and copy number variations of 43 serum samples were obtained using next-generation sequencing (Hiseq, Illumina). We analyzed the relationship between the microRNA changes and patient prognosis. Results: miR-142a-5p cluster expression levels in serum exosomes were most correlated with the poor prognosis of cutaneous squamous cell carcinoma. Exosomal miR-142-5p expression levels in serum were significantly higher (P< 0.01) in patients with late-stage disease than in those with early-stage disease. In addition, patients with recurrent tumors showed high levels of miR-142-5p. Conclusion: miR-142-5p expression level may be an essential marker for predicting patient prognosis and to help decide whether to undergo additional systemic chemotherapy after surgery. secretes exosomes containing miRNAs and transmits signals to their respective receiving cells. Our results show that the serum miRNA-142-5p cluster could be a potential biomarker for predicting the recurrence of cutaneous cell carcinoma. The TNM stage is typically already 3 or higher when lymphatic metastasis occurs. However, despite recurrence, no lymph node metastasis was observed at the time of diagnosis. An analysis of the serum external miRNA expression profile in this study showed that four serum exosomal miRNAs (miRNA-106a-3p, miRNA-10a-3p, miR-142-5p, miRNA-192a-5p) were adjusted to match cutaneous cell carcinoma progression. Among them, only miRNA-142-5p was found to be statistically related to overall survival. MiRNAs predictive ability","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75880550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Quilting Technique for Reduction of Seroma in Mastectomy Patient-A Prospective Study","authors":"","doi":"10.29011/2574-710x.10134","DOIUrl":"https://doi.org/10.29011/2574-710x.10134","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80148446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Mobile Application for Childhood Cancer Survivorship Care: A Cross Sectional Survey Study","authors":"","doi":"10.29011/2574-710x.10136","DOIUrl":"https://doi.org/10.29011/2574-710x.10136","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85301433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular-Targeted Hyperthermia Therapy for Breast Cancer Cells","authors":"Yokoyama","doi":"10.29011/2574-710x.010133","DOIUrl":"https://doi.org/10.29011/2574-710x.010133","url":null,"abstract":"Hyperthermia is a minimally invasive cancer therapy that sensitizes cancer cells to chemotherapy and radiotherapy by improving the tumor microenvironment such as blood flow and acidic conditions. Because stress-related and anti-apoptotic proteins exert a cytoprotective effect and are often up-regulated in many types of cancer, molecular-targeted therapy may be useful in combination with hyperthermia. In the present study, we found that hyperthermia induced myeloid-cell leukemia 1 (MCL-1) anti-apoptotic protein expression among several apoptosis-related molecules. MCL-1 knockdown promoted the anti-tumor effect of hyperthermia by increasing apoptosis. miR-29b-3p, which downregulated MCL-1 protein expression, also promoted the antitumor effect of hyperthermia. Moreover, we showed that hyperthermia facilitated the translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) stress-related protein to the nucleus and expression of the downstream target heme oxygenase 1 (HO-1) antioxidant gene. The knockdown of Nrf2 promoted the anti-tumor effect of hyperthermia by suppressing expression of stress-related genes such as HO-1 and NAD (P) H quinone dehydrogenase 1 and by increasing reactive oxygen species production. Our results suggest the potential usefulness of molecular-targeted hyperthermia therapy using nucleic acid medicine.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81151030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Safety And Efficacy of Iron Supplementation in Cancer Patients","authors":"A. Antonuzzo, O. Cuomo, Marco, Danova","doi":"10.29011/2574-710x.10131","DOIUrl":"https://doi.org/10.29011/2574-710x.10131","url":null,"abstract":"It has been widely demonstrated that in patients with chronic diseases or cancer, iron homeostasis may be dysregulated. Iron deficiency with or without anemia is a frequent complication in cancer patients and may be associated, even in the absence of anemia, with weakness, fatigue, and worsening of quality of life, which may ameliorated by iron therapy. The present review will analyze the scientific evidence about iron deficiency diagnosis and management with particular regards with the different formulations of iron available on the market. Iron deficiency is usually treated with oral iron salts, however this approach is very usually accompanied by gastrointestinal side effects, which consequently reduce the compliance with treatment. Interestingly, an innovative oral iron formulation with ferric pyrophosphate covered by a phospholipids plus sucrose esters of fatty acids matrix that, represent a valid option since it is more efficacious and tolerable than oral iron salts and has emerged as a first choice of treatment.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78799086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}